-
Condition:
- Drug Test, 1 Test Single Dip Device, OXY100, CLIA Waived, 25/bx
-
Learn more:
-
MFR:
Abbott Toxicology
Ships from MFI Medical
-
MPN: WDOX-114
- Phone: (800) 727-7846
Frequently asked questions
Does the Abbott Tdip Card offer rapid drug screening?
Yes, the Abbott Toxicology Tdip Card is specifically designed for rapid, qualitative drug screening. Its single-dip device format emphasizes speed and convenience for point-of-care (POC) testing.
Key features supporting rapid decentralized testing include:
- CLIA Waived Status: This classification enables its use in Physician Office Laboratories (POLs) and other decentralized settings that require less stringent laboratory certification.
- Single Dip Device Format: The design allows for quick specimen introduction and immediate visual results interpretation.
- Versatile Panel Configurations: The card is available in options ranging from a single-analyte test (OXY100) up to a comprehensive 10-Panel drug screen, allowing you to customize testing to specific needs.
Does CLIA Waived status simplify testing?
Yes, the CLIA Waived status is a top selling point for the Abbott Toxicology Tdip Card, significantly simplifying the drug screening process.
This designation means the product meets the Clinical Laboratory Improvement Amendments (CLIA) requirements for low-complexity testing, offering several key advantages for facilities:
- Simplified Regulatory Burden: It complies with waived testing requirements, easing the regulatory burden compared to higher-complexity tests.
- Point-of-Care Suitability: It is ideal for use in decentralized settings like physician offices and occupational health clinics.
- Ease of Use: The single-dip device format is straightforward, designed to minimize the need for specialized laboratory equipment or highly trained personnel for administration and result interpretation.
What CLIA Waived Tdip card configurations are available?
The Abbott Toxicology Tdip Cards are CLIA Waived rapid screening devices, allowing for easy, presumptive drug testing in various clinical environments. All configurations are sold in boxes containing 25 tests.
The following single-dip device configurations are offered:
- 1-Panel Test: Screens for Oxymorphone (OXY100).
- 5-Panel Test (Variant 1): Screens for Amphetamine (AMP1000), Cocaine (COC300), Opiates (OPI2000), Phencyclidine (PCP25), and Tetrahydrocannabinol (THC50).
- 5-Panel Test (Variant 2): Screens for Amphetamine (AMP1000), Cocaine (COC300), Methamphetamine (MET1000), Opiates (OPI2000), and Tetrahydrocannabinol (THC50).
- 10-Panel Test: Provides comprehensive screening for Amphetamine (AMP1000), Barbiturates (BAR300), Benzodiazepines (BZO300), Buprenorphine (BUP10), Cocaine (COC300), Methamphetamine (MET1000), Methadone (MTD300), Opiates (OPI2000), Oxymorphone (OXY100), and Tetrahydrocannabinol (THC50).
How many Tdip Cards are included per box?
All configurations of the Abbott Toxicology Tdip Cards are packaged with 25 individual tests per box (25/bx).
Is this Tdip Card used for rapid point-of-care screening?
Yes, the Abbott Toxicology Tdip Card is specifically designed for rapid, convenient drug screening in point-of-care (POC) environments.
Its effectiveness for quick screening workflows stems from several key features:
- CLIA Waived Status: The device is classified as CLIA Waived, meaning it meets the standards for simple, low-complexity testing. This allows it to be used outside of traditional high-complexity laboratories in settings like clinical offices or occupational health facilities.
- Rapid Immunoassay: It functions as a rapid screening immunoassay for the qualitative detection of specific drugs and their metabolites in human urine, ensuring immediate results.
- Single-Dip Format: The test utilizes a simple, single-dip device mechanism, which streamlines the testing procedure and aids in rapid interpretation.
Are these Tdip cards suitable for point-of-care testing?
Yes, the Abbott Toxicology Tdip Cards are ideal for point-of-care (POC) testing environments.
Their suitability is primarily due to their CLIA Waived Status (Clinical Laboratory Improvement Amendments). This designation certifies them as simple, low-complexity tests, making them appropriate for use in clinics, workplaces, or other non-laboratory settings that comply with CLIA standards for waived testing.
Features supporting rapid, on-site screening include:
- Rapid Testing Format: They utilize a simple single-dip device for quick, qualitative screening of drugs of abuse.
- Configurable Options: Versatile configurations are available, ranging from 1-panel to comprehensive 10-panel kits, allowing facilities to tailor screening based on specific needs.
Is the Tdip Card suitable for rapid point-of-care testing?
Yes, the Abbott Toxicology Tdip Card is designed specifically for rapid drug screening in point-of-care (POC) settings.
Key features that make it ideal for these environments include:
- CLIA Waived Status: This designation allows its use in facilities meeting Clinical Laboratory Improvement Amendments waived testing requirements, simplifying regulatory compliance for physician offices or occupational settings.
- Single-Dip Format: It uses a user-friendly, single-dip device methodology for qualitative detection of drugs and metabolites in human urine.
- Versatile Configurations: The cards offer flexibility with options ranging from a single-test device (like OXY100) up to a comprehensive 10-panel screening device, accommodating diverse testing needs.
Where are these CLIA Waived tests intended for use?
The Abbott Toxicology Tdip Cards are specifically designed for use in point-of-care testing (POCT) environments.
Since these devices are CLIA Waived, they are approved for use in facilities that require simple, low-complexity testing, minimizing regulatory burdens compared to traditional high-complexity laboratories.
They are ideal for various professional settings, including:
- Clinical Settings: For rapid patient diagnostics and monitoring.
- Occupational Health Programs: Suitable for workplace drug screening, such as pre-employment or random testing.
- Non-Laboratory Settings: Any location needing streamlined, on-site diagnostics and quick result interpretation.
Is this CLIA Waived test suitable for point-of-care use?
Yes, the Abbott Toxicology Tdip Card is designated as CLIA Waived. This critical status confirms that the device meets federal criteria for simple, low-complexity testing, making it highly suitable for use outside of traditional high-complexity laboratory environments.
This ease of use and compliance makes it ideal for rapid, qualitative drug screening at the point of care (POC) in settings such as:
- Clinical Environments: Doctor’s offices, urgent care centers, and medical facilities requiring immediate results.
- Occupational Health: Essential for workplace drug testing programs (e.g., pre-employment or random screenings).
- On-Site Testing: Any professional setting needing compliant, decentralized testing with minimal regulatory complexity.
Do the Tdip Cards offer multiple panel options?
Yes, the Abbott Toxicology Tdip Cards are available in several versatile configurations to meet diverse screening needs. All devices are designated as CLIA Waived for ease of use in point-of-care settings, and each option is supplied in boxes of 25 units.
The available configurations include:
- 1-Panel Test (OXY100): Screens specifically for Oxycodone.
- 5-Panel Tests (Two Options):
- Option A: Detects AMP1000, COC300, OPI2000, PCP25, and THC50.
- Option B: Detects AMP1000, COC300, MET1000, OPI2000, and THC50.
- 10-Panel Comprehensive Test: Offers the most extensive screening, detecting AMP1000, BAR300, BZO300, BUP10, COC300, MET1000, MTD300, OPI2000, OXY100, and THC50.